. The purpose of this pooled analysis of the XANTUS, XANAP, and XANTUS-EL studies was to assess the global safety profile of rivaroxaban in routine clinical practice.
METHODS
We performed a pre-planned pooled analysis of the studies in the XANTUS program (the XANTUS, XANAP, and XANTUS-EL studies). Detailed methods have been described previously (14, 15) . The XANTUS, XANAP, and XANTUS-EL studies were international, prospective, observational, noninterventional cohort studies (16, 17) . In order to limit selection bias, participating investigators were asked to enroll consecutive patients by screening and documenting patients with a diagnosis of AF in an anonymous patient log file. The screening documentation was completed before eligible, consenting patients signed an informed consent form, and it was not permitted for patient-related data to be collected from the remaining ineligible or nonconsenting patients. Table 1 . Mean patient age was 70.5 years, and 57.1% of patients were male.
Comorbidities associated with stroke and/or bleeding events were common and included congestive heart failure (21.2%), hypertension (76.2%), diabetes mellitus (22.3%), and prior stroke/non-CNS SE/TIA (21.3%). There were 190 treatment-emergent major bleeding events in 172 patients (1.7 events/100 patient-years) ( Table 2 Table 3 ).
In total, 3,796 patients (34.1%) had a treatmentemergent AE and 1,647 patients (14.6%) had a treatment-emergent SAE. As expected, the incidence of major bleeding and stroke/non-CNS SE increased with age; the incidence rates of major bleeding in patients <65, 65 to 75, and >75 years of age were 0.8, 1.4, and 2.9 events/100 patient-years, respectively. Values are n (%) unless otherwise indicated. *Fatal bleeding using narrow definitions (the patient experienced a treatment-emergent major bleeding event and died within 30 days of the major bleeding event and the adjudicated primary cause of death was either intracranial hemorrhage or extracranial bleeding. †hemorrhagic strokes and hemorrhagic transformations of ischemic stroke were adjudicated as both stroke and major bleeding. Multiple reasons for major bleedings were possible.
AE ¼ adverse event; RBC ¼ red blood cell; other abbreviations as in Table 1 .
Global Safety of Rivaroxaban
The corresponding rates of stroke/non-CNS SE were 0.5, 1. CHADS 2 ¼ congestive heart failure, hypertension, age $75 years, diabetes mellitus, prior stroke or transient ischemic attack; CHA 2 DS 2 -VASc ¼ congestive heart failure, hypertension, age $75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism, vascular disease, age 65-74 years, sex category (female); other abbreviations as in Figure 3. same date as the treatment interruption, however, the possibility that the outcome event occurred before the interruption cannot be excluded.
Rivaroxaban dose was changed at least once in 639 patients (5.7%); dose was changed only once in the majority of these patients (n ¼ 567), with AEs being the most common reason for a dose change. Dose changes were more common in patients with CrCl <50 ml/min (10.6%) than in those with a CrCl $50 ml/min or unknown CrCl (5.1%). Major bleeding events were mostly treated medically, and nonspecific reversal agents were rarely used; of the 172 patients who experienced a major bleeding event, use of tranexamic acid was documented in 5 patients, blood coagulation factors in 3 patients, and the hemostatic agent etamsylate in 2 patients.
DISCUSSION
The entire XANTUS program, which analyzed data from 11,121 patients worldwide, is the largest prospective, observational, noninterventional study to date of a single DOAC for stroke prevention in patients with AF. The results from this pooled analysis showed that patients with AF throughout the world had low rates of stroke and major bleeding in the first year after initiating rivaroxaban, and that fatal and critical organ bleeding events, including ICH, were rare, occurring in #0.6% of patients.
In the XANTUS global pooled analysis, incidence rates of major outcomes, which were centrally adjudicated, were numerically lower than those reported in rivaroxaban-treated patients from other real-world investigator bias during patient selection; major bleeding definitions (ISTH major bleeding vs. major bleeding identified from coding in patient databases); differences in patient baseline characteristics and risk profiles (e.g., differences in prior use of antithrombotics); as well as differences in the rivaroxaban doses received (Online Table 4 ). The rates of major bleeding, stroke/non-CNS SE and all-cause death were generally similar between patients with and without prior antithrombotic therapy (Online Figure 2 , Online Table 3 ). This suggested that the differences in event rates observed between regions were unlikely to be due to differences in prior antithrombotic therapy. 
